Spectroscopic imaging of the pilocarpine model of human epilepsy suggests that early NAA reduction predicts epilepsy

William A. Gomes, F. A. Lado, N. C. De Lanerolle, K. Takahashi, C. Pan, H. P. Hetherington

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Reduced hippocampal N-acetyl aspartate (NAA) is commonly observed in patients with advanced, chronic temporal lobe epilepsy (TLE). It is unclear, however, whether an NAA deficit is also present during the clinically quiescent latent period that characterizes early TLE. This question has important implications for the use of MR spectroscopic imaging (MRSI) in the early identification of patients at risk for TLE. To determine whether NAA is diminished during the latent period, we obtained high-resolution 1H spectroscopic imaging during the latent period of the rat pilocarpine model of human TLE. We used actively detuneable surface reception and volume transmission coils to enhance sensitivity and a semiautomated voxel shifting method to accurately position voxels within the hippocampi. During the latent period, 2 and 7 d following pilocarpine treatment, hippocampal NAA was significantly reduced by 27.5 ± 6.9% (P < 0.001) and 17.3 ± 6.9% (P < 0.001) at 2 and 7 d, respectively. Quantitative estimates of neuronal loss at 7 d (2.3 ± 7.7% reduction; P = 0.58, not significant) demonstrate that the NAA deficit is not due to neuron loss and therefore likely represents metabolic impairment of hippocampal neurons during the latent phase. Therefore, spectroscopic imaging provides an early marker for metabolic dysfunction in this model of TLE.

Original languageEnglish (US)
Pages (from-to)230-235
Number of pages6
JournalMagnetic Resonance in Medicine
Volume58
Issue number2
DOIs
StatePublished - Aug 2007

Fingerprint

Pilocarpine
Temporal Lobe Epilepsy
Epilepsy
Neurons
Hippocampus
N-acetylaspartate

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Gomes, W. A., Lado, F. A., De Lanerolle, N. C., Takahashi, K., Pan, C., & Hetherington, H. P. (2007). Spectroscopic imaging of the pilocarpine model of human epilepsy suggests that early NAA reduction predicts epilepsy. Magnetic Resonance in Medicine, 58(2), 230-235. https://doi.org/10.1002/mrm.21310

Spectroscopic imaging of the pilocarpine model of human epilepsy suggests that early NAA reduction predicts epilepsy. / Gomes, William A.; Lado, F. A.; De Lanerolle, N. C.; Takahashi, K.; Pan, C.; Hetherington, H. P.

In: Magnetic Resonance in Medicine, Vol. 58, No. 2, 08.2007, p. 230-235.

Research output: Contribution to journalArticle

Gomes, WA, Lado, FA, De Lanerolle, NC, Takahashi, K, Pan, C & Hetherington, HP 2007, 'Spectroscopic imaging of the pilocarpine model of human epilepsy suggests that early NAA reduction predicts epilepsy', Magnetic Resonance in Medicine, vol. 58, no. 2, pp. 230-235. https://doi.org/10.1002/mrm.21310
Gomes, William A. ; Lado, F. A. ; De Lanerolle, N. C. ; Takahashi, K. ; Pan, C. ; Hetherington, H. P. / Spectroscopic imaging of the pilocarpine model of human epilepsy suggests that early NAA reduction predicts epilepsy. In: Magnetic Resonance in Medicine. 2007 ; Vol. 58, No. 2. pp. 230-235.
@article{334d9e80e37c456bb3256e64104956a6,
title = "Spectroscopic imaging of the pilocarpine model of human epilepsy suggests that early NAA reduction predicts epilepsy",
abstract = "Reduced hippocampal N-acetyl aspartate (NAA) is commonly observed in patients with advanced, chronic temporal lobe epilepsy (TLE). It is unclear, however, whether an NAA deficit is also present during the clinically quiescent latent period that characterizes early TLE. This question has important implications for the use of MR spectroscopic imaging (MRSI) in the early identification of patients at risk for TLE. To determine whether NAA is diminished during the latent period, we obtained high-resolution 1H spectroscopic imaging during the latent period of the rat pilocarpine model of human TLE. We used actively detuneable surface reception and volume transmission coils to enhance sensitivity and a semiautomated voxel shifting method to accurately position voxels within the hippocampi. During the latent period, 2 and 7 d following pilocarpine treatment, hippocampal NAA was significantly reduced by 27.5 ± 6.9{\%} (P < 0.001) and 17.3 ± 6.9{\%} (P < 0.001) at 2 and 7 d, respectively. Quantitative estimates of neuronal loss at 7 d (2.3 ± 7.7{\%} reduction; P = 0.58, not significant) demonstrate that the NAA deficit is not due to neuron loss and therefore likely represents metabolic impairment of hippocampal neurons during the latent phase. Therefore, spectroscopic imaging provides an early marker for metabolic dysfunction in this model of TLE.",
author = "Gomes, {William A.} and Lado, {F. A.} and {De Lanerolle}, {N. C.} and K. Takahashi and C. Pan and Hetherington, {H. P.}",
year = "2007",
month = "8",
doi = "10.1002/mrm.21310",
language = "English (US)",
volume = "58",
pages = "230--235",
journal = "Magnetic Resonance in Medicine",
issn = "0740-3194",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Spectroscopic imaging of the pilocarpine model of human epilepsy suggests that early NAA reduction predicts epilepsy

AU - Gomes, William A.

AU - Lado, F. A.

AU - De Lanerolle, N. C.

AU - Takahashi, K.

AU - Pan, C.

AU - Hetherington, H. P.

PY - 2007/8

Y1 - 2007/8

N2 - Reduced hippocampal N-acetyl aspartate (NAA) is commonly observed in patients with advanced, chronic temporal lobe epilepsy (TLE). It is unclear, however, whether an NAA deficit is also present during the clinically quiescent latent period that characterizes early TLE. This question has important implications for the use of MR spectroscopic imaging (MRSI) in the early identification of patients at risk for TLE. To determine whether NAA is diminished during the latent period, we obtained high-resolution 1H spectroscopic imaging during the latent period of the rat pilocarpine model of human TLE. We used actively detuneable surface reception and volume transmission coils to enhance sensitivity and a semiautomated voxel shifting method to accurately position voxels within the hippocampi. During the latent period, 2 and 7 d following pilocarpine treatment, hippocampal NAA was significantly reduced by 27.5 ± 6.9% (P < 0.001) and 17.3 ± 6.9% (P < 0.001) at 2 and 7 d, respectively. Quantitative estimates of neuronal loss at 7 d (2.3 ± 7.7% reduction; P = 0.58, not significant) demonstrate that the NAA deficit is not due to neuron loss and therefore likely represents metabolic impairment of hippocampal neurons during the latent phase. Therefore, spectroscopic imaging provides an early marker for metabolic dysfunction in this model of TLE.

AB - Reduced hippocampal N-acetyl aspartate (NAA) is commonly observed in patients with advanced, chronic temporal lobe epilepsy (TLE). It is unclear, however, whether an NAA deficit is also present during the clinically quiescent latent period that characterizes early TLE. This question has important implications for the use of MR spectroscopic imaging (MRSI) in the early identification of patients at risk for TLE. To determine whether NAA is diminished during the latent period, we obtained high-resolution 1H spectroscopic imaging during the latent period of the rat pilocarpine model of human TLE. We used actively detuneable surface reception and volume transmission coils to enhance sensitivity and a semiautomated voxel shifting method to accurately position voxels within the hippocampi. During the latent period, 2 and 7 d following pilocarpine treatment, hippocampal NAA was significantly reduced by 27.5 ± 6.9% (P < 0.001) and 17.3 ± 6.9% (P < 0.001) at 2 and 7 d, respectively. Quantitative estimates of neuronal loss at 7 d (2.3 ± 7.7% reduction; P = 0.58, not significant) demonstrate that the NAA deficit is not due to neuron loss and therefore likely represents metabolic impairment of hippocampal neurons during the latent phase. Therefore, spectroscopic imaging provides an early marker for metabolic dysfunction in this model of TLE.

UR - http://www.scopus.com/inward/record.url?scp=34547931096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547931096&partnerID=8YFLogxK

U2 - 10.1002/mrm.21310

DO - 10.1002/mrm.21310

M3 - Article

C2 - 17654595

AN - SCOPUS:34547931096

VL - 58

SP - 230

EP - 235

JO - Magnetic Resonance in Medicine

JF - Magnetic Resonance in Medicine

SN - 0740-3194

IS - 2

ER -